title: Reverse Cardiac Remodeling: A Marker of Better Prognosis in Heart Failure.
abstract: In heart failure syndrome, myocardial dysfunction causes an increase in neurohormonal activity, which is an adaptive and compensatory mechanism in response to the reduction in cardiac output. Neurohormonal activity is initially stimulated in an attempt to maintain compensation; however, when it remains increased, it contributes to the intensification of clinical manifestations and myocardial damage. Cardiac remodeling comprises changes in ventricular volume as well as the thickness and shape of the myocardial wall. With optimized treatment, such remodeling can be reversed, causing gradual improvement in cardiac function and consequently improved prognosis.
authors.affiliation: Serviço de Cardiologia, Hospital Santa Marcelina, São Paulo, SP, Brazil.
authors.forename: José Rosino de Araújo Rocha
authors.initials: JR
authors.lastname: Reis Filho
authors.affiliation: Serviço de Cardiologia, Hospital Santa Marcelina, São Paulo, SP, Brazil.
authors.forename: Juliano Novaes
authors.initials: JN
authors.lastname: Cardoso
authors.affiliation: Serviço de Cardiologia, Hospital Santa Marcelina, São Paulo, SP, Brazil.
authors.forename: Cristina Martins dos Reis
authors.initials: CM
authors.lastname: Cardoso
authors.affiliation: Serviço de Cardiologia, Hospital Santa Marcelina, São Paulo, SP, Brazil.
authors.forename: Antonio Carlos
authors.initials: AC
authors.lastname: Pereira-Barretto
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D006333:Heart Failure / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D011379:Prognosis; D013318:Stroke Volume / Q000502:physiology; D013997:Time Factors; D020257:Ventricular Remodeling / Q000187:drug effects* / Q000502:physiology
chemical_list: D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors